324,378 research outputs found
Severe panuveitis in neuro-Behçet’s disease in Malaysia: a case series
No full textKhairuddin Othman,1 Ahmad Tajudin Liza-Sharmini,1 Mohtar Ibrahim,1 John Tharakan,2 Ryoji Yanai,3 Embong Zunaina1 1Department of Ophthalmology, 2Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia; 3Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan Abstract: Behçet’s disease (BD) is a multisystemic disease that is very rare in Malaysia. About 5% of patients develop central nervous system involvement, termed neuro-Behçet’s. Neuro-Behçet’s is one of the most serious causes of long-term morbidity and mortality. We report two cases of neuro-Behçet’s associated with uveitis (ocular BD) highlighting the clinical presentation, diagnostic measurement, and therapeutic management of these cases.Keywords: Behçet’s disease, Behçet’s syndrome, parenchymal neuro-Behçet’s, uveiti
Dissociative recombination of BeH
No full textWe report a theoretical study of dissociative recombination (DR) of BeH+ by
low energy electron impact, using previously computed molecular data as input for a
Multichannel Quantum Defect Theory (MQDT) approach. Three electronic symmetries of BeH,
2Π, 2Σ+, and 2Δ have been included in the
calculations. We present cross sections and thermal rate coefficients ready to be used in
the modelling of the BeH+ abundance in the interstellar medium and stellar
atmosphere
Update on the diagnosis and management of Behçet’s disease
No full textRyo Rokutanda, Mitsumasa Kishimoto, Masato Okada Immuno-Rheumatology Center, St Luke’s International Hospital, Tokyo, Japan Abstract: Behçet’s disease is a multi-organ disorder that is more common in countries around the Silk Road, and manifests as mucosal ulcers and skin lesions, and with ocular involvement. As a systemic disease, it can also involve gastrointestinal organs and the central nervous or cardiovascular systems. Although the etiology of Behçet's disease is not clearly identified, the pathogenesis of the disease is most commonly hypothesized as a profound inflammatory response triggered by an infectious agent in a genetically susceptible host. As there are no single specific manifestations or specific diagnostic tests, various diagnostic criteria have been proposed around the world, and, among them, the International Study Group criteria have been most commonly used. As the clinical expression of Behçet's disease is heterogeneous, the treatment should be individualized based on involved organs, severity of the disease, and patient's background. The choice of therapeutic agents is limited by lack of clinical trials and is based largely on case reports, case series, and several open-label clinical trials. Corticosteroids, colchicine, and traditional immunosuppressive agents, including azathioprine and cyclosporine, have been used for the treatment of Behçet’s disease. Recently, tumor necrosis factor (TNF) inhibitors have become available for several rheumatic diseases, and considerable published data suggest that TNF inhibitors represent an important therapeutic advance for patients with severe and resistant disease, as well as for those with contraindications or intolerance to these treatments. Keywords: Behçet’s disease, therapeutic agents, etiology, diagnosi
Synthetic spectra of BeH, BeD and BeT for emission modeling in JET plasmas
No full textA theoretical model for isotopologues of beryllium monohydride, BeH, BeD and BeT, A to X visible and X to X infrared rovibronic spectra is presented. The MARVEL procedure is used to compute empirical rovibronic energy levels for BeH, BeD and BeT, using experimental transition data for the X , A , and C states. The energy levels from these calculations are then used in the program Duo to produce a potential energy curve for the ground state, X , and to fit an improved potential energy curve for the first excited state, A , including a spin–orbit coupling term, a Λ-doubling state to state (A–X states) coupling term, and Born–Oppenheimer breakdown terms for both curves. These, along with a previously computed ab initio dipole curve for the X and A states are used to generate vibrational-rotational wavefunctions, transition energies and A-values. From the transition energies and Einstein coefficients, accurate assigned synthetic spectra for BeH and its isotopologues are obtained at given rotational and vibrational temperatures. The BeH spectrum is compared with a high resolution hollow-cathode lamp spectrum and the BeD spectrum with high resolution spectra from JET giving effective vibrational and rotational temperatures. Full A–X and X–X line lists are given for BeH, BeD and BeT and provided as supplementary data on the ExoMol website
Det beh\uf6vs en nationell databas f\uf6r solcellsanl\ue4ggningar
No full textEnergimyndigheten b\uf6r f\ue5 i uppdrag att ansvara f\uf6r en nationell databas som inneh\ue5ller alla n\ue4tanslutna solcellsanl\ue4ggningar i Sverige, s\ue5 att statistik kanf\uf6ras l\uf6pande och tillg\ue4ngligg\uf6ras p\ue5 nationell, regional och lokal niv\ue5. Solenergibranschen beh\uf6ver b\ue4ttre statistik f\uf6r att kunna utv\ue4rdera marknadsutvecklingen. Elhandelsbolag, eln\ue4tbolag och Svenska kraftn\ue4t beh\uf6ver statistik f\uf6r att kunna planera f\uf6r framtida elhandel, el\uf6verf\uf6ring och eln\ue4tsutbyggnad. Energimyndigheten och politiker beh\uf6ver statistik f\uf6r att f\uf6lja upp resultatet avolika styrmedel. Regering, l\ue4nsstyrelser, regioner,energikontor, kommuner beh\uf6ver statistik f\uf6r att kunna f\uf6lja utbyggnaden av f\uf6rnybar energigenereringnationellt, regionalt och lokalt
Face Detection System / Chan Beh Teng
No full textThe aim of this project is to replicate on a computer what humans beings are able to do so effortlessly - detect the presence of the faces in their field of vision. To a layman, it may appear trivial, but to actually implement the necessary steps leading to successful execution of this in n algorithm is difficult and still an unsolved problem in computer vision.The proposed Face Detection System is an application that automates the detection of frontal human faces(s) in a given image. The System perform all tasks including image pre-processing, analysis and output. The user merely present it with the image. The system takes as input a 24 bit RGB colour image which containts face(s). Before the detection process begins, the system pre-processes the image into a format required by the system. The system will generate an output where every detected face will be indicated with a rectangle on a copy of the original image. The method used for detecting face is a combination of color based technique and template matching. A gray-scale image is generated from the original input image. Skin regions are then separated from skin regions by segmenting the gray-scale image. After that, the system will locate the frontal human face(s) within the skin regions, using template matching. The Face Detection System is implemented in visual Basic 6.0 The system was developed based on the Unified Process,which uses object-oriented paradigm as the basis of software development
Behçet’s syndrome: providing integrated care
No full textSinem Nihal Esatoglu,1 Zekayi Kutlubay,2 Didar Ucar,3 Ibrahim Hatemi,4 Ugur Uygunoglu,5 Aksel Siva,5 Gulen Hatemi1 1Division of Rheumatology, Department of Internal Medicine, 2Department of Dermatology, 3Department of Ophthalmology, 4Division of Gastroenterology, Department of Internal Medicine 5Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey Abstract: Behçet’s syndrome (BS) is a multisystem vasculitis that presents with a variety of mucocutaneous manifestations such as oral and genital ulcers, papulopustular lesions and erythema nodosum as well as ocular, vascular, gastrointestinal and nervous system involvement. Although it occurs worldwide, it is especially prevalent in the Far East and around the Mediterranean Sea. Male gender and younger age at disease onset are associated with a more severe disease course. The management of BS depends on the severity of symptoms. If untreated, morbidity and mortality are considerably high in patients with major organ involvement. Multidisciplinary patient care is essential for the management of BS, as it is for other multisystem diseases. Rheumatologists, dermatologists, ophthalmologists, neurologists, cardiovascular surgeons and gastroenterologists are members of the multidisciplinary team. In this study, we reviewed the epidemiology, etiology, diagnostic criteria sets, clinical findings and treatment of BS and highlighted the importance of the multidisciplinary team in the management of BS. Keywords: Behçet disease, multidisciplinary care, diagnosis, treatment, vasculitis, epidemiology, managemen
Synthetic spectra of BeH, BeD and BeT for emission modeling in JET plasmas
No full textA theoretical model for isotopologues of beryllium monohydride, BeH, BeD and BeT, A 2P to X 2Σ+ visible and X 2Σ+ to X 2Σ+ infrared rovibronic spectra is presented. The MARVEL procedure is used to compute empirical rovibronic energy levels for BeH, BeD and BeT, using experimental transition data for the X 2Σ+, A 2P, and C 2Σ+ states. The energy levels from these calculations are then used in the program Duo to produce a potential energy curve for the ground state, X 2S, and to fit an improved potential energy curve for the first excited state, A 2P, including a spin-orbit coupling term, a λ-doubling state to state (A-X states) coupling term, and Born-Oppenheimer breakdown terms for both curves. These, along with a previously computed ab initio dipole curve for the X and A states are used to generate vibrational-rotational wavefunctions, transition energies and A-values. From the transition energies and Einstein coefficients, accurate assigned synthetic spectra for BeH and its isotopologues are obtained at given rotational and vibrational temperatures. The BeH spectrum is compared with a high resolution hollow-cathode lamp spectrum and the BeD spectrum with high resolution spectra from JET giving effective vibrational and rotational temperatures. Full A-X and X-X line lists are given for BeH, BeD and BeT and provided as supplementary data on the ExoMol website
Managing Behçet’s disease: An update on current and emerging treatment options
No full textP LA van Daele, J H Kappen, P M van Hagen, J AM van LaarDepartment of Internal Medicine, Department of Immunology, Erasmus MC, ‘s Gravendijkwal 230, 3015 Ce Rotterdam, The NetherlandsAbstract: Behçet’s disease is an autoinflammatory vasculitis of unknown origin characterized by recurrent oral and genital ulcers, uveitis, arthritis and skin lesions. Additionally, involvement of the gastrointestinal tract, central nervous system and large vessels may occur. The disease is prevalent in countries along the ancient Silk Road from Eastern Asia to the Mediterranean Basin. Many treatment modalities are currently available. The choice of treatment depends on organ involvement and severity of disease. Topical treatment with corticosteroids is often sufficient for mucocutaneous involvement, however for more severe disease with vasculitis or neurological involvement a more aggressive approach is warranted. Newer drugs (biologicals) influencing cytokines and thereby T-cell function are promising with an acceptable side effect profile. Unfortunately, reimbursement of the costs of biologicals for rare disease is still a problem in various countries. In this report we discuss the current treatment modalities for Behçet’s disease.Keywords: Behçet’s disease, biologicals, treatmen
Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behçet’s disease
No full textAtsuko Katsuyama,1 Sentaro Kusuhara,1 Ryuto Nishisho,1 Wataru Matsumiya,1 Atsushi Azumi,2 Makoto Nakamura1 1Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan; 2Department of Ophthalmology, Kobe Kaisei Hospital, Nada-ku, Kobe 657-0068, Japan Purpose: This study aimed to evaluate the long-term efficacy and safety of infliximab (IFX) and cyclosporine (CsA) combination therapy for refractory uveoretinitis in Behçet’s disease (BD). Patients and methods: The study involved a retrospective review of the medical records of 11 patients with Behçet’s uveoretinitis refractory to conventional treatment who had been treated with IFX+CsA combination therapy. The frequency of ocular inflammatory attacks and a Behçet’s disease ocular attack score 24 (BOS24) were used as indices for the evaluation of efficacy during each 6-month period prior to and following initiation of therapy. For the assessment of safety, adverse events (AEs) were recorded throughout the treatment period. Results: The patients had received IFX+CsA combination therapy for 5.6±2.3 years. The frequency of ocular attacks per 6-month period decreased markedly from 2.9±1.6 during the baseline period to 0.6±0.9 during months 1–6, 0.5±0.9 during months 7–12, 0.3±0.5 during months 13–18, 0.3±0.7 during months 19–24, and 0.0±0.0 thereafter (P=0.003). The BOS24 score per ocular attack significantly decreased from 5.2±2.4 during the baseline period to 1.5±2.1 during months 1–6, 1.7±3.1 during months 7–12, 1.6±2.9 during months 13–18, and 0.4±1.0 during months 19–24 (P=0.002). No serious AEs were observed, with the exception of urinary tract infection and cataract progression. Two patients exhibited transient elevation of the serum creatinine level, which was normalized following a reduction in the dose of CsA. Conclusion: For refractory Behçet’s uveoretinitis, IFX+CsA combination therapy offers a promising treatment option as it appears to have an acceptable safety profile and can reduce the frequency and severity of ocular inflammatory attacks over a long period of time. Keywords: Behçet’s disease, uveitis, infliximab, cyclosporine, efficacy, safet
- …
